Literature DB >> 20680537

Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma.

Teresa Warchoł1, Lukasz Kruszyna, Margarita Lianeri, Andrzej Roszak, Paweł P Jagodziński.   

Abstract

We examined the distribution of the CCND1 A870G (rs9344) polymorphic variant in patients with cervical cancer (n = 129) and healthy individuals (n = 288) in a sample of a Polish cohort. We showed that patients with advanced cervical cancer bearing the CCND1 A/A and A/G genotypes displayed a 1.811-fold increased risk of cervical cancer (95% CI = 1.150-2.852, p = 0.0098). We also found a significantly higher frequency of the CCND1 870A allele in patients with cancer than in controls, p = 0.0116. Our investigation confirmed that the CCND1 870A gene variant may be a genetic risk factor in the incidence of advanced cervical cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20680537     DOI： 10.1007/s12253-010-9293-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  36 in total

1.  Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.

Authors:  Xuwei Hou; Sili Wang; Yuling Zhou; Ziliang Xu; Yao Zou; Xiaofan Zhu; Mingzhe Han; Tianxiang Pang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer.

Authors:  Lizhong Wang; Tomonori Habuchi; Takeshi Takahashi; Kenji Mitsumori; Toshiyuki Kamoto; Yoshiyuki Kakehi; Hideaki Kakinuma; Kazunari Sato; Akira Nakamura; Osamu Ogawa; Tetsuro Kato
Journal:  Carcinogenesis       Date:  2002-02       Impact factor: 4.944

Review 4.  The epidemiology of human papillomavirus infections.

Authors:  Janet G Baseman; Laura A Koutsky
Journal:  J Clin Virol       Date:  2005-03       Impact factor: 3.168

5.  Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.

Authors:  David A Solomon; Ying Wang; Sejal R Fox; Tah C Lambeck; Sarah Giesting; Zhengdao Lan; Adrian M Senderowicz; Claudio J Conti; Erik S Knudsen
Journal:  J Biol Chem       Date:  2003-05-12       Impact factor: 5.157

6.  Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer.

Authors:  J Bartkova; J Lukas; H Müller; M Strauss; B Gusterson; J Bartek
Journal:  Cancer Res       Date:  1995-02-15       Impact factor: 12.701

7.  Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells.

Authors:  Ala-Eddin Al Moustafa; William D Foulkes; Annick Wong; Houda Jallal; Gerald Batist; Qunyan Yu; Meenhard Herlyn; Piotr Sicinski; Moulay A Alaoui-Jamali
Journal:  Oncogene       Date:  2004-07-01       Impact factor: 9.867

8.  Alternate splicing produces a novel cyclin D1 transcript.

Authors:  D C Betticher; N Thatcher; H J Altermatt; P Hoban; W D Ryder; J Heighway
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

9.  Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor.

Authors:  KyungWon Huh; Xiaobo Zhou; Hiroyuki Hayakawa; Je-Yoel Cho; Towia A Libermann; Jianping Jin; J Wade Harper; Karl Munger
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

10.  Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk.

Authors:  Ummiye V Onay; Kirsimari Aaltonen; Laurent Briollais; Julia A Knight; Noel Pabalan; Outi Kilpivaara; Irene L Andrulis; Carl Blomqvist; Heli Nevanlinna; Hilmi Ozcelik
Journal:  BMC Cancer       Date:  2008-01-14       Impact factor: 4.430
View more
  5 in total

1.  Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients.

Authors:  Biljana Jekic; Ljiljana Lukovic; Vera Bunjevacki; Vera Milic; Ivana Novakovic; Tatjana Damnjanovic; Jelena Milasin; Branka Popovic; Nela Maksimovic; Nemanja Damjanov; Goran Radunovic; Ljiljana Kovacevic; Maja Krajinovic
Journal:  Eur J Clin Pharmacol       Date:  2012-07-05       Impact factor: 2.953

2.  Cyclin D1 (CCND1) G870A polymorphisms and cervical cancer susceptibility: a meta-analysis based on ten case-control studies.

Authors:  Yongfu Wu; Hui Fu; Hanbin Zhang; Haohai Huang; Miao Chen; Li Zhang; Huiling Yang; Dongyun Qin
Journal:  Tumour Biol       Date:  2014-04-16

3.  Association of CCND1 gene polymorphism with cervical cancer susceptibility in Caucasian population: a meta-analysis.

Authors:  Mei Yang; Hongmei Zhu; Ting Hu; Shanling Liu; He Wang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  CCND1 gene polymorphic variants in patients with differentiated thyroid carcinoma.

Authors:  Szymon Hryhorowicz; Katarzyna Ziemnicka; Marta Kaczmarek-Ryś; Justyna Hoppe-Gołębiewska; Andrzej Pławski; Marzena Skrzypczak-Zielińska; Małgorzata Szkudlarek; Monika Gołąb; Bartłomiej Budny; Marek Ruchała; Ryszard Słomski
Journal:  Oncol Lett       Date:  2014-10-15       Impact factor: 2.967

5.  Association between cyclin D1 G870A polymorphism and cervical cancer risk: a cumulative meta-analysis involving 2,864 patients and 3,898 controls.

Authors:  Yuan-Yuan Hu; Rong Zheng; Chong Guo; Yu-Ming Niu
Journal:  Diagn Pathol       Date:  2014-09-10       Impact factor: 2.644
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.